iQure Pharma Secures $600K in Commitments in Early Closing to Research Neuropathic Pain Therapies

Updated: Sep 3

Keiretsu Forum and Business Angel Investors Provide Funding to Support Research into Neuropathic Pain Compounds iQ-007 and iQ-008


Princeton, NJ, August 31, 2022 ─ iQure Pharma Inc. (iQure), a Princeton-based global biotech company, today confirmed completion of Early Closing as part of its Series A investment, which will support ongoing research into non-opioid therapeutics for neuropathic pain.


iQure Pharma has secured over $600k of commitments to date and is supported by Keiretsu Mid-Atlantic, together with business angels associated with Keiretsu’s Accelerator Fund and Keiretsu Northwest, to advance the preclinical development of iQure’s novel therapeutics, iQ-007 and iQ-008. In addition, both compounds are supported by non-dilutive funding through the NIH epilepsy (ETSP) and NIH pain (PSPP) programs.


“We are so thankful to all of our early investors,” said iQure Chief Executive Officer Pawel Zolnierczyk. “Their support of our novel therapeutics for neuropathic pain, validates our strong experimental data. Along with support from the NIH, this latest investment enables iQure to further develop our assets and increase our value. With the support of our investors and researchers, we are proud to be a part of the biotech community developing promising therapies of the future.”


iQ-007 has demonstrated positive results, including NIH ETSP tests, which show that the compound has the ability to treat pain, epilepsy and other potentially neurodegenerative diseases. iQ-008, a novel analgesic compound, has achieved significant progress within the NIH PSPP program, and is advancing to the next stage in the Preclinical Screening Platform for Pain (PSPP), under the NIH HEAL Initiative, a program designed to facilitate the identification of potential non-addictive treatments for acute and chronic pain conditions and alternatives to opioid analgesics.


Chronic pain is one of the most common chronic conditions in the United States. In 2019, 20.4% of adults experienced chronic pain and 7.4% had high-impact chronic pain that severely limited daily life or work activities. An estimated twenty million Americans experience some sort of peripheral neuropathy, one of the most severe forms of chronic pain.



About iQure Pharma

A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for neuropathic pain, epilepsy and wide-ranging neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.


100 views

Recent Posts

See All

Life Sciences industry experts Michael D. Webb and Brian Cain bring extensive expertise in strategic pharmaceutical growth DELAWARE, April 07, 2022 ─iQure Pharma Inc. (iQure), a US-based global biotec